Mersana Therapeutics has reported encouraging preliminary data from the Phase 1 trial of its lead antibody-drug conjugate, emiltatug ledadotin (Emi-Le), which targets B7-H4 in patients with advanced ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating ...
lidERA Breast Cancer is a phase III, randomized, open-label, multicentre study evaluating the efficacy and safety of adjuvant giredestrant versus standard-of-care endocrine therapy in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback